Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase III NExUS trial of sorafenib in NSCLC does not meet primary endpoint

June 15, 2010

Telormedix begins phase I/II TMX-101 trial in non-muscle-invasive bladder cancer

June 15, 2010

R-7160 evaluated in phase I/II trial in solid tumors

June 15, 2010

UCB presents novel PI3K inhibitors

June 15, 2010

MGMTP140K-modified CD34+ stem cells efficiently engrafted into patients with glioblastoma

June 15, 2010

Nerviano Medical Sciences discloses new HSP 90 inhibitors

June 15, 2010

Cediranib to enter phase II trial in advanced biliary tract cancers

June 14, 2010

Trials suggest dasatinib or nilotinib could replace imatinib as first-line CML therapy

June 14, 2010

S*BIO completes enrollment in phase II SB-1518 trials in myelofibrosis

June 11, 2010

HGS reports phase II data on mapatumumab in advanced multiple myeloma

June 11, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.